NTPDase1/CD39 Ectonucleotidase Is Necessary for Normal Arterial Diameter Adaptation to Flow

Int J Mol Sci. 2023 Oct 10;24(20):15038. doi: 10.3390/ijms242015038.

Abstract

NTPDase1/CD39, the major vascular ectonucleotidase, exerts thrombo-immunoregulatory function by controlling endothelial P2 receptor activation. Despite the well-described release of ATP from endothelial cells, few data are available regarding the potential role of CD39 as a regulator of arterial diameter. We thus investigated the contribution of CD39 in short-term diameter adaptation and long-term arterial remodeling in response to flow using Entpd1-/- male mice. Compared to wild-type littermates, endothelial-dependent relaxation was modified in Entpd1-/- mice. Specifically, the vasorelaxation in response to ATP was potentiated in both conductance (aorta) and small resistance (mesenteric and coronary) arteries. By contrast, the relaxing responses to acetylcholine were supra-normalized in thoracic aortas while decreased in resistance arteries from Entpd1-/- mice. Acute flow-mediated dilation, measured via pressure myography, was dramatically diminished and outward remodeling induced by in vivo chronic increased shear stress was altered in the mesenteric resistance arteries isolated from Entpd1-/- mice compared to wild-types. Finally, changes in vascular reactivity in Entpd1-/- mice were also evidenced by a decrease in the coronary output measured in isolated perfused hearts compared to the wild-type mice. Our results highlight a key regulatory role for purinergic signaling and CD39 in endothelium-dependent short- and long-term arterial diameter adaptation to increased flow.

Keywords: ATP; NTPDase1/CD39; flow-mediated vasodilation; shear stress; vascular remodeling.

MeSH terms

  • Adenosine Triphosphate*
  • Animals
  • Antigens, CD / genetics
  • Apyrase / physiology
  • Endothelial Cells*
  • Endothelium, Vascular
  • Male
  • Mice
  • Vasodilation

Substances

  • Adenosine Triphosphate
  • CD39 antigen
  • Antigens, CD
  • Apyrase

Grants and funding

G.K. was a recipient of a fellowship from the Heart and Stroke Foundation of Canada in partnership with the Canadian Institutes of Health Research and from Fondation de France. J.S. was supported by a joint grant from The Canadian Hypertension Society and Pfizer, and by grants from the Heart & Stroke Foundation of Quebec and from the Canadian Institutes of Health Research. J.F. was a recipient of a fellowship from the Société Française d’Hypertension Artérielle (SFHTA). S.C.R. got financial support from the NIH.